SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2016
A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.
Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.Advances in therapy · 2022Pooled it
- Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.BMC public health · 2022Pooled it
- Intersectoral costs of sexually transmitted infections (STIs) and HIV: a systematic review of cost-of-illness (COI) studies.BMC health services research · 2021Pooled it
- Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.PharmacoEconomics · 2021Pooled it
- How relevant are social costs in economic evaluations? The case of Alzheimer's disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- [Social costs of diseases: How relevant are they for economic evaluations?]Revista espanola de salud publica · 2018Pooled it
- The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review.PharmacoEconomics · 2017Pooled it
- Trial
- Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- The Gift of Time, How Do I Want to Spend It? Exploring Preferences for Time Allocation Among Women with and without a Breast Cancer Diagnosis.Applied health economics and health policy · 2025Article
- Insights and networks: methodological assessment and scientometric analysis of economic evaluations in dentistry.BMC health services research · 2024Article
- The need for a broad perspective when assessing value-for-money for out-of-hours primary care.Primary health care research & development · 2024Review
- Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects.PharmacoEconomics · 2023Article
- Partially different? The importance of general equilibrium in health economic evaluations: An application to nocturia.Health economics · 2023Article
- Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China.BMJ global health · 2022Review
- Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach.Current oncology (Toronto, Ont.) · 2022Article
- Cost-Effectiveness of an Exercise Programme That Provided Group or Individual Training to Reduce the Fall Risk in Healthy Community-Dwelling People Aged 65-80: A Secondary Data Analysis.Healthcare (Basel, Switzerland) · 2021Article
- Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs.PharmacoEconomics · 2021Article
- Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.ClinicoEconomics and outcomes research : CEOR · 2021Review
- Considering the societal perspective in economic evaluations: a systematic review in the case of depression.Health economics review · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Productivity costs can strongly impact cost-effectiveness outcomes. This study investigated the impact in the context of expensive hospital drugs. This study aimed to: (1) investigate the effect of productivity costs on cost-effectiveness outcomes, (2) determine whether economic evaluations of expensive drugs commonly include productivity costs related to paid and unpaid work, and (3) explore potential reasons for excluding productivity costs from the economic evaluation. We conducted a systematic literature review to identify economic evaluations of 33 expensive drugs. We analysed whether evaluations included productivity costs and whether inclusion or exclusion was related to the study population's age, health and national health economic guidelines. The impact on cost-effectiveness outcomes was assessed in studies that included productivity costs. Of 249 identified economic evaluations of expensive drugs, 22 (9 %) included productivity costs related to paid work. One study included unpaid productivity. Mostly, productivity cost exclusion could not be explained by the study population's age and health status, but national guidelines appeared influential. Productivity costs proved often highly influential. This study indicates that productivity costs in economic evaluations of expensive hospital drugs are commonly and inconsistently ignored in economic evaluations. This warrants caution in interpreting and comparing the results of these evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.